Plasmocin prot
Plasmocin™
For treatment and prevention of Mycoplasma contamination of cel culture
PRODUCT INFORMATION
In contrast to most anti-Mycoplasma compounds that act solely
in
Content:
vitro,
Plasmocin™ is active on Mycoplasma present in cel culture
Plasmocin™ is supplied as 1 ml tubes containing a sterile, yel ow
medium, and on intracel ular Mycoplasma found in some specialized
mammalian cells. The two antibiotics comprising
Plasmocin™ are
-
ant-mpt: 2x 1ml at 25mg/ml (50mg). For elimination of
actively transported into mammalian cel s providing a synergistic
killing effect on intracellular Mycoplasma without any apparent
-
ant-mpp: 5x 2ml at 2.5mg/ml (25mg). For prevention of
adverse effect on cellular metabolism. This benefit insures that
after being treated with
Plasmocin™, a cel culture is not reinfected by
Shipping and Storage:
Mycoplasma released from the intracellular compartments of
Plasmocin™ is shipped at room temperature. Upon receipt, it should
infected cells following antibiotic removal. At high concentrations
be stored at 4°C for immediate use and is stable at this temperature for
of
Plasmocin™, slowdown of cel growth rate may be observed.
several weeks. If
Plasmocin™ is not to be used immediately, then
This slowing down is mainly due to the inhibition of mitochondria
freeze at -20°C for long term storage.
respiration by
Plasmocin™. However when
Plasmocin™ is removed
Plasmocin™ is stable for at least two years when stored at -20°C.
from culture medium, cells return rapidly to their normal growth
Note: Presence of crystals does not alter properties of the product.
rate. The anti-Mycoplasma activity of
Plasmocin™ is unaltered in
Vortex the tube until the crystals disappear.
cell culture medium containing up to 20% serum.
Quality Control:
Activity of
Plasmocin™ is rigorously control ed by physicochemical
RESISTANCE TO PLASMOCIN™
In repeated experiments aimed to determine the mutation rate of
Mycoplasma hominis,
Mycoplasma bovis and
Acholeplasma vituli to
GENERAL PRODUCT USE
Plasmocin™, no resistance in liquid cultures has ever been identified,
Plasmocin™ is used to cure cel lines infected by Mycoplasma and
indicating a possible mutation rate lower than 10-9. Therefore,
related cel wal -less bacteria.
Plasmocin™ can also be used as a routine
development of resistant Mycoplasma strains is highly unlikely.
addition in liquid media to prevent Mycoplasma and more general y
bacterial contamination in smal and large animal cel cultures.
Treatment of Mycoplasma Infected Cel Cultures:
BACKGROUND
Plasmocin™ treatment (ant-mpt) requires lit le hands-on manipulation
Recent reports estimate Mycoplasma contamination in up to 63% of
and is completed in only two weeks. Typical y,
Plasmocin™ is used at
al cel cultures. Mycoplasma cannot be detected by visual inspection
25 µg/ml which represents a 1:1000 dilution of the 25 mg/ml stock solution.
and may not noticeably affect cel culture growth rates. However,
Working concentration of
Plasmocin™ ranges from 12.5 to 37.5 µg/ml.
Mycoplasma infection has been shown to alter DNA, RNA and protein
synthesis, introduce chromosomal aberrations and cause alterations or
1- Split an actively dividing culture of cel s into medium containing
modifications of host cel plasma membrane antigens.
12-25µg/ml of
Plasmocin™.
Plasmocin
2- Remove and replace with fresh
Plasmocin™ containing medium
™ is a new generation of bactericidal antibiotic preparation
stronglyactiveonMycoplasmainfectedcel s.Itisactiveatlowconcentrations
on a broad range of gram positive and gram negative bacteria otherwise
3. For maintenance of a Mycoplasma free culture, continue the use of
resistant to the mixture of streptomycin and penicil in antibiotics
Plasmocin™ at a concentration of 5µg/ml.
Note: If Mycoplasma elimination is not completed after a two week
treatment, you may continue the treatment for an additional week
DESCRIPTION / PROPERTIES
and/or increase the concentration to 37.5 µg/ml.
Plasmocin™ contains two newly developed bactericidal components:
Maintenance or prophylactic use against Mycoplasma infections:
one acts on the protein synthesis machinery by interfering with
To prevent Mycoplasma and related cell wall-less bacteria
ribosome translation, and the other acts on DNA replication by
contaminations of cell cultures that have been previously tested
interfering with the replication fork. These two specific and separate
to be contamination-free, use
Plasmocin™ prevention (ant-mpp)
targets are found only in Mycoplasma and many other bacteria,
at a concentration of 5 µg/ml that represents a 1:500 dilution of the
and are completely absent in eukaryotic cells.
TECHNICAL SUPPORTToll free (US): 888-457-5873Outside US: (+1) 858-457-5873Europe: +33 562-71-69-39E-mail:
[email protected]
Source: http://www.shdsyy.com.cn/web/themes/165/userfiles/download/2013/3/15/rroteghcoxvby3l.pdf
Andrewes and the Caroline Divines’ Teaching on the Blessed Paper for the Ecumenical Society of the Blessed Virgin Mary. November, 2000. Neither are we unmindful to bless Thee, for the most holy, pure, highly blessed, the Mother of God, Mary the eternal Virgin, with all the Saints . So prayed Lancelot Andrewes in the Orthodox tradition frequently. Andrewes who ended his life as bishop of W
Chapter I – Literature Survey. Heme oxygenase (HO) is the rate-limiting enzyme in the degradation of heme, converting heme to CO, biliverdin and free iron. Biliverdin is subsequently reduced to bilirubin by biliverdin reductase (BVR). Three HO isoforms have been identified: the stress- inducible HO-1 and the constitutive HO-2/HO-3 isoforms which are expressed under basal conditions. The HO